Shopping Cart
- Remove All
Your shopping cart is currently empty
3,4-O-Isopropylidene-shikimic acid (3,4-O-Isopropylidene shikimic acid) exhibits significant anti-inflammatory, anti-thrombosis, antioxidant, and analgesic effects, and provides protective benefits against trinitrobenzenesulfonic acid-induced experimental colitis in rats, likely because of its antioxidant properties.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $68 | In Stock | |
| 5 mg | $168 | In Stock | |
| 10 mg | $248 | In Stock | |
| 25 mg | $413 | In Stock | |
| 50 mg | $590 | In Stock | |
| 100 mg | $798 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $173 | In Stock |
| Description | 3,4-O-Isopropylidene-shikimic acid (3,4-O-Isopropylidene shikimic acid) exhibits significant anti-inflammatory, anti-thrombosis, antioxidant, and analgesic effects, and provides protective benefits against trinitrobenzenesulfonic acid-induced experimental colitis in rats, likely because of its antioxidant properties. |
| In vitro | 3,4-O-Isopropylidene shikimic acid (ISA,1-100 micromol/L) effectively reduced PMN adhesion to TNF-alpha-induced HUVEC with the inhibitory rate from 17.2 % to 53.5 % and exerted no effect on PMN adhesion to normal HUVEC. Adhesion molecule ICAM-1 surface protein and mRNA expression induced by TNF-alpha (400 kU/L) were significantly inhibited by ISA. In addition, the cell viability of HUVEC was unchanged 48 h after treatment with ISA[1] |
| Synonyms | 3,4-O-Isopropylidene shikimic acid |
| Molecular Weight | 214.22 |
| Formula | C10H14O5 |
| Cas No. | 183075-03-8 |
| Smiles | [H][C@]12OC(C)(C)O[C@@]1([H])[C@H](O)CC(=C2)C(O)=O |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 60 mg/mL (280.09 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (9.34 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.